Evolve Biologics to break ground for new manufacturing facility in Texas

The facility will be the first to use Evolve’s innovative PlasmaCap EBA technology to produce plasma-derived therapeutics

According to Jim Caggiano, Evolve's CEO, the next-generation technology is "poised to revolutionise the plasma-derived therapeutics industry" by harvesting significantly higher yields of these proteins from human plasma through a cleaner, more efficient process, compared with existing fractionation technologies.

The technology uses proprietary affinity adsorbents in expanded bed adsorption (EBA) chromatography to capture plasma proteins directly from plasma or fractionated plasma materials without using precipitating solvents such as ethanol.

The new 200,000-sq. ft commercial facility, which will be the foundation of the company's future growth and global strategy, will have production capacity to process one million liters of plasma annually, with a planned expansion to 2 million liters.

As Evolve is currently in the process of commercialising an innovative portfolio of product candidates, the facility will initially produce intravenous immunoglobulin (IVIG) and human serum albumin (HSA).

The company has said it expects to hire approximately 300 new employees to work in the facility during the next 3 years.